89bio to Present at Upcoming Investor Conferences
August 03 2020 - 4:05PM
89bio, Inc. (Nasdaq: ETNB), a clinical-stage biopharmaceutical
company focused on the development and commercialization of
innovative therapies for the treatment of liver and
cardio-metabolic diseases, today announced that Rohan Palekar, the
company’s Chief Executive Officer, will participate in a fireside
chat at the BTIG Virtual Biotechnology Conference 2020 on Monday,
August 10 , 2020 at 11:30 AM ET and the Canaccord Genuity 40th
Annual Growth Conference on Wednesday, August 12, 2020 at 10:00 AM
ET.
The live and archived webcast of the
presentation will be accessible from the company’s website at
https://ir.89bio.com/events-and-presentations. The replay of the
webcast will be available on the company’s website.
About 89bio
89bio is a clinical-stage biopharmaceutical
company focused on the development and commercialization of
innovative therapies for the treatment of liver and
cardio-metabolic diseases. The company’s lead product candidate,
BIO89-100, is being developed for the treatment of NASH and for the
treatment of SHTG. BIO89-100 is a specifically engineered
glycoPEGylated analog of FGF21 that is currently in a proof of
concept Phase 1b/2a clinical trial in patients with NASH or NAFLD
and a high risk of NASH. 89bio is headquartered in San Francisco
with operations in Herzliya, Israel. Visit 89bio.com for more
information.
Investor Contact: Ryan Martins Chief Financial Officer
investors@89bio.com
Media Contact: Lori Rosen LDR Communications 917-553-6808
lori@ldrcommunications.com
89bio (NASDAQ:ETNB)
Historical Stock Chart
From Mar 2024 to Apr 2024
89bio (NASDAQ:ETNB)
Historical Stock Chart
From Apr 2023 to Apr 2024